SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Obagi Medical Products, Inc. In Connection With The Sale Of The Company To Valeant Pharmaceuticals International, Inc.

Levi & Korsinsky is investigating the Board of Directors of Obagi Medical Products, Inc. (“Obagi” or the “Company”) (NasdaqGS: OMPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Valeant Pharmaceuticals International, Inc. (NYSE: VRX).

Click here to learn how to join the action: http://zlk.9nl.com/obagi-medical-products-ompi/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Obagi shareholders will receive $19.75 for each share of Obagi common stock they own. The investigation concerns whether the Obagi Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether Valeant Pharmaceuticals International, Inc. is underpaying for Obagi shares, thus unlawfully harming Obagi stockholders.

If you own common stock in Obagi and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or http://zlk.9nl.com/obagi-medical-products-ompi/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

The Five Dumbest Things on Wall Street: April 12

The Five Dumbest Things on Wall Street: April 12

Merz Withdrawal Frees Obagi-Valeant Merger

Merz Withdrawal Frees Obagi-Valeant Merger

Valeant Buys Obagi Medical for $360 Million

Valeant Buys Obagi Medical for $360 Million

Obagi Medical Products Inc. Stock Downgraded (OMPI)

Obagi Medical Products Inc. Stock Downgraded (OMPI)

5 Hated Stocks Set to Soar on Earnings

5 Hated Stocks Set to Soar on Earnings